Search results
Jun 4, 2024 · Illumina, Inc. announced that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's May 16, 2024, annual meeting. Illumina To Webcast Upcoming May 2024 Investor Conference. 5/15/2024. Illumina, Inc. announced that its executives will be speaking at the following investor ...
Jan 9, 2023 · Whole-genome sequencing of 35,000 de-identified, diverse genomic DNA samples will begin this month. SAN DIEGO, Jan. 9, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced an agreement with Amgen, a global ...
Jun 3, 2024 · GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ: ILMN) currently held separate from Illumina, Inc. under the terms of the Interim Measures Order of the European Commission. For more information, visit grail.com. Illumina investors: Salli Schwartz 858-291-6421 IR@illumina.com Illumina media: Bonny Fowler 740-641-5579 PR@illumina.com
Reach out for information about our products and services or get answers to questions about our technology. Get in touch. *For in vitro diagnostic use. Contact an Illumina representative for regional availability. Illumina offers a broad range of sequencing and microarray products for diverse genomic analysis applications.
Jan 10, 2022 · Multiple innovative partnerships with healthcare companies, research institutions, and multiomic developers, along with new groundbreaking technologies, including a new SBS chemistry and long-read capabilities, position Illumina to accelerate genomic adoption and improve human health globally Illumina, Inc. (NASDAQ:ILMN) Chief Executive Officer, Francis deSouza, discussed today the company's ...
Jun 26, 2023 · Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through ...
Jun 26, 2024 · Overcoming the challenges in PMS2 high-homology regions for improved detection of pathogenic variants associated with Lynch syndrome. Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.
